Updates in diabetic peripheral neuropathy

Kelsey Juster-Switlyk, A Gordon Smith, Kelsey Juster-Switlyk, A Gordon Smith

Abstract

Diabetes has become one of the largest global health-care problems of the 21 (st) century. According to the Centers for Disease Control and Prevention, the population prevalence of diabetes in the US is approaching 10% and is increasing by 5% each year. Diabetic neuropathy is the most common complication associated with diabetes mellitus. Diabetes causes a broad spectrum of neuropathic complications, including acute and chronic forms affecting each level of the peripheral nerve, from the root to the distal axon. This review will focus on the most common form, distal symmetric diabetic polyneuropathy. There has been an evolution in our understanding of the pathophysiology and the management of diabetic polyneuropathy over the past decade. We highlight these new perspectives and provide updates from the past decade of research.

Keywords: Diabetes mellitus; diabetic peripheral neuropathy; polyneuropathy.

Conflict of interest statement

Competing interests: The authors declare that they have no competing interests.

No competing interests were disclosed.

References

    1. Hossain P, Kawar B, El Nahas M: Obesity and diabetes in the developing world--a growing challenge. N Engl J Med. 2007;356(3):213–5. 10.1056/NEJMp068177
    1. Singh R, Kishore L, Kaur N: Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol Res. 2014;80:21–35. 10.1016/j.phrs.2013.12.005

    2. F1000 Recommendation

    1. Boulton AJ: Management of Diabetic Peripheral Neuropathy. Clin Diabetes. 2005;23(1):9–15. 10.2337/diaclin.23.1.9
    1. Tesfaye S, Selvarajah D: Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012;28(Suppl 1):8–14. 10.1002/dmrr.2239
    1. Tesfaye S, Vileikyte L, Rayman G, et al. : Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629–38. 10.1002/dmrr.1225
    1. Tesfaye S, Boulton AJ, Dyck PJ, et al. : Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–93. 10.2337/dc10-1303
    1. Quattrini C, Tesfaye S: Understanding the impact of painful diabetic neuropathy. Diabetes Metab Res Rev. 2003;19(Suppl 1):S2–8. 10.1002/dmrr.360
    1. Callaghan BC, Cheng HT, Stables CL, et al. : Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11(6):521–34. 10.1016/S1474-4422(12)70065-0
    1. Argoff CE, Cole BE, Fishbain DA, et al. : Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc. 2006;81(4 Suppl):S3–11. 10.1016/S0025-6196(11)61474-2
    1. Sadosky A, Mardekian J, Parsons B, et al. : Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complications. 2015;29(2):212–7. 10.1016/j.jdiacomp.2014.10.013

    2. F1000 Recommendation

    1. American Diabetes Association: Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033–46. 10.2337/dc12-2625

    2. F1000 Recommendation

    1. Gordois A, Scuffham P, Shearer A, et al. : The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26(6):1790–5. 10.2337/diacare.26.6.1790
    1. Bansal V, Kalita J, Misra UK: Diabetic neuropathy. Postgrad Med J. 2006;82(964):95–100. 10.1136/pgmj.2005.036137
    1. Tracy JA, Dyck PJ: The spectrum of diabetic neuropathies. Phys Med Rehabil Clin N Am. 2008;19(1):1–26, v. 10.1016/j.pmr.2007.10.010
    1. Gibbons CH, Freeman R: Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol. 2010;67(4):534–41. 10.1002/ana.21952

    2. F1000 Recommendation

    1. Ellenberg M: Diabetic neuropathic cachexia. Diabetes. 1974;23(5):418–23. 10.2337/diab.23.5.418
    1. Tran C, Philippe J, Ochsner F, et al. : Acute painful diabetic neuropathy: an uncommon, remittent type of acute distal small fibre neuropathy. Swiss Med Wkly. 2015;145:w14131. 10.4414/smw.2015.14131

    2. F1000 Recommendation

    1. Tesfaye S, Malik R, Harris N, et al. : Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia. 1996;39(3):329–35. 10.1007/s001250050449
    1. Bril V, Tomioka S, Buchanan RA, et al. : Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med. 2009;26(3):240–6. 10.1111/j.1464-5491.2009.02667.x
    1. Rosenberg NR, Portegies P, de Visser M, et al. : Diagnostic investigation of patients with chronic polyneuropathy: evaluation of a clinical guideline. J Neurol Neurosurg Psychiatry. 2001;71(2):205–9. 10.1136/jnnp.71.2.205
    1. Dyck PJ, Overland CJ, Low PA, et al. : Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve. 2010;42(2):157–64. 10.1002/mus.21661
    1. Smith AG, Singleton JR: The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy. Arch Intern Med. 2004;164(9):1021–5. 10.1001/archinte.164.9.1021
    1. Shtein RM, Callaghan BC: Corneal confocal microscopy as a measure of diabetic neuropathy. Diabetes. 2013;62(1):25–6. 10.2337/db12-1114
    1. England JD, Gronseth GS, Franklin G, et al. : Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72(2):185–92. 10.1212/01.wnl.0000336370.51010.a1
    1. England JD, Gronseth GS, Franklin G, et al. : Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. 2009;1(1):14–22. 10.1016/j.pmrj.2008.11.011
    1. Beulens JW, Hart HE, Kuijs R, et al. : Influence of duration and dose of metformin on cobalamin deficiency in type 2 diabetes patients using metformin. Acta Diabetol. 2015;52(1):47–53. 10.1007/s00592-014-0597-8

    2. F1000 Recommendation

    1. Zilliox L, Russell JW: Treatment of diabetic sensory polyneuropathy. Curr Treat Options Neurol. 2011;13(2):143–59. 10.1007/s11940-011-0113-1
    1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–86. 10.1056/NEJM199309303291401
    1. Linn T, Ortac K, Laube H, et al. : Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients. Metabolism. 1996;45(12):1508–13. 10.1016/S0026-0495(96)90180-8
    1. Duckworth W, Abraira C, Moritz T, et al. : Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39. 10.1056/NEJMoa0808431

    2. F1000 Recommendation

    1. Ismail-Beigi F, Craven T, Banerji MA, et al. : Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–30. 10.1016/S0140-6736(10)60576-4

    2. F1000 Recommendation

    1. Callaghan BC: The Impact of the Metabolic Syndrome on Neuropathy.
    1. Tesfaye S, Stevens LK, Stephenson JM, et al. : Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39(11):1377–84. 10.1007/s001250050586
    1. Tesfaye S, Chaturvedi N, Eaton SE, et al. : Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–50. 10.1056/NEJMoa032782
    1. Callaghan B, Feldman E: The metabolic syndrome and neuropathy: therapeutic challenges and opportunities. Ann Neurol. 2013;74(3):397–403. 10.1002/ana.23986

    2. F1000 Recommendation

    1. Cameron NE, Eaton SE, Cotter MA, et al. : Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44(11):1973–88. 10.1007/s001250100001
    1. Malik RA, Tesfaye S, Thompson SD, et al. : Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia. 1993;36(5):454–9. 10.1007/BF00402283
    1. Callaghan BC, Hur J, Feldman EL: Diabetic neuropathy: one disease or two? Curr Opin Neurol. 2012;25(5):536–41. 10.1097/WCO.0b013e328357a797
    1. Smith AG, Russell J, Feldman EL, et al. : Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29(6):1294–9. 10.2337/dc06-0224

    2. F1000 Recommendation

    1. Balducci S, Iacobellis G, Parisi L, et al. : Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006;20(4):216–23. 10.1016/j.jdiacomp.2005.07.005
    1. Singleton JR, Marcus RL, Jackson JE, et al. : Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol. 2014;1(10):844–9. 10.1002/acn3.125
    1. Stevens JA, Phelan EA: Development of STEADI: a fall prevention resource for health care providers. Health Promot Pract. 2013;14(5):706–14. 10.1177/1524839912463576
    1. Ziegler D, Low PA, Litchy WJ, et al. : Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054–60. 10.2337/dc11-0503
    1. Oyenihi AB, Ayeleso AO, Mukwevho E, et al. : Antioxidant strategies in the management of diabetic neuropathy. Biomed Res Int. 2015;2015:515042. 10.1155/2015/515042

    2. F1000 Recommendation

    1. Hotta N, Akanuma Y, Kawamori R, et al. : Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. 2006;29(7):1538–44. 10.2337/dc05-2370
    1. Bril V, Buchanan RA: Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care. 2006;29(1):68–72. 10.2337/diacare.29.01.06.dc05-1447
    1. Chalk C, Benstead TJ, Moore F: Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev. 2007; (4):CD004572. 10.1002/14651858.CD004572.pub2
    1. Fraser DA, Diep LM, Hovden IA, et al. : The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care. 2012;35(5):1095–7. 10.2337/dc11-1895
    1. Griebeler ML, Morey-Vargas OL, Brito JP, et al. : Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med. 2014;161(9):639–49. 10.7326/M14-0511

    2. F1000 Recommendation

    1. Callaghan BC, Feldman EL: Painful diabetic neuropathy: many similarly effective therapies with widely dissimilar costs. Ann Intern Med. 2014;161(9):674–5. 10.7326/M14-2157
    1. Iyer S, Tanenberg RJ: Pharmacologic management of diabetic peripheral neuropathic pain. Expert Opin Pharmacother. 2013;14(13):1765–75. 10.1517/14656566.2013.811490
    1. Callaghan B, Kerber K, Langa KM, et al. : Longitudinal patient-oriented outcomes in neuropathy: Importance of early detection and falls. Neurology. 2015;85(1):71–9. 10.1212/WNL.0000000000001714

    2. F1000 Recommendation

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir